关注
Edwin Santiago Lobaton Barrero
Edwin Santiago Lobaton Barrero
Estudiante de Trabajo Social
在 unicolmayor.edu.co 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer …
F Magro, P Gionchetti, R Eliakim, S Ardizzone, A Armuzzi, ...
Journal of Crohn's and Colitis 11 (6), 649-670, 2017
17232017
The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease
M Harbord, V Annese, SR Vavricka, M Allez, M Barreiro-de Acosta, ...
Journal of Crohn's and Colitis 10 (3), 239-254, 2016
8222016
3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: surgical management and special situations
P Gionchetti, A Dignass, S Danese, FJ Magro Dias, G Rogler, PL Lakatos, ...
Journal of Crohn's and Colitis 11 (2), 135-149, 2017
7902017
European Crohn’s and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis …
F Magro, P Gionchetti, R Eliakim, S Ardizzone, A Armuzzi, ...
J Crohns Colitis 11 (6), 649-670, 2017
3742017
Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients
M Chaparro, I Ordás, E Cabré, V Garcia-Sanchez, G Bastida, M Peñalva, ...
Inflammatory bowel diseases 19 (7), 1404-1410, 2013
3272013
Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease
MJ Casanova, M Chaparro, E Domenech, M Barreiro-de Acosta, ...
Official journal of the American College of Gastroenterology| ACG 108 (3 …, 2013
2642013
Evaluation of the risk of relapse in ulcerative colitis according to the degree of mucosal healing (Mayo 0 vs 1): a longitudinal cohort study
M Barreiro-de Acosta, N Vallejo, D de la Iglesia, L Uribarri, I Bastón, ...
Journal of Crohn's and Colitis 10 (1), 13-19, 2016
2092016
Prevalence of malnutrition and nutritional characteristics of patients with inflammatory bowel disease
MJ Casanova, M Chaparro, B Molina, O Merino, R Batanero, ...
Journal of Crohn's and Colitis 11 (12), 1430-1439, 2017
1902017
European Crohn’s and Colitis Organisation
M Harbord, V Annese, SR Vavricka, M Allez, M Barreiro-de Acosta, ...
The first European evidence-based consensus on extra-intestinal …, 2016
1902016
Psychological factors are associated with changes in the health-related quality of life in inflammatory bowel disease
M Iglesias-Rey, M Barreiro-de Acosta, F Caamaño-Isorna, IV Rodríguez, ...
Inflammatory bowel diseases 20 (1), 92-102, 2014
1722014
Infliximab salvage therapy after failure of ciclosporin in corticosteroid‐refractory ulcerative colitis: a multicentre study
M Chaparro, P Burgueño, E Iglesias, J Panés, F Muñoz, G Bastida, ...
Alimentary pharmacology & therapeutics 35 (2), 275-283, 2012
1242012
Emigration to western industrialized countries: A risk factor for developing inflammatory bowel disease
M Barreiro-de Acosta, A Alvarez Castro, R Souto, M Iglesias, A Lorenzo, ...
Journal of Crohn's and Colitis 5 (6), 566-569, 2011
1222011
Evolution after anti-TNF discontinuation in patients with inflammatory bowel disease: a multicenter long-term follow-up study
MJ Casanova, M Chaparro, V García-Sánchez, O Nantes, E Leo, ...
Official journal of the American College of Gastroenterology| ACG 112 (1 …, 2017
1182017
Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab
C Taxonera, J Estelles, I Fernández‐Blanco, O Merino, I Marín‐Jiménez, ...
Alimentary pharmacology & therapeutics 33 (3), 340-348, 2011
1182011
European Crohn’s and Colitis Organisation topical review on complementary medicine and psychotherapy in inflammatory bowel disease
J Torres, P Ellul, J Langhorst, A Mikocka-Walus, M Barreiro-de Acosta, ...
Journal of Crohn's and Colitis 13 (6), 673-685e, 2019
1102019
Clinical outcomes of golimumab as first, second or third anti-TNF agent in patients with moderate-to-severe ulcerative colitis
C Taxonera, C Rodriguez, F Bertoletti, L Menchen, J Arribas, M Sierra, ...
Inflammatory bowel diseases 23 (8), 1394-1402, 2017
922017
Short and long‐term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry
M Chaparro, A Garre, E Ricart, M Iborra, F Mesonero, I Vera, S Riestra, ...
Alimentary pharmacology & therapeutics 48 (8), 839-851, 2018
912018
Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series
M Barreiro-de Acosta, O García-Bosch, J Gordillo, M Mañosa, L Menchén, ...
European journal of gastroenterology & hepatology 24 (7), 756-758, 2012
862012
Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease
F Argüelles-Arias, L Castro-Laria, T Lobatón, M Aguas-Peris, ...
Digestive diseases and sciences 58 (10), 2949-2954, 2013
792013
Fecal calprotectin as predictor of relapse in patients with inflammatory bowel disease under maintenance infliximab therapy
R Ferreiro-Iglesias, M Barreiro-de Acosta, M Otero Santiago, ...
Journal of clinical gastroenterology 50 (2), 147-151, 2016
782016
系统目前无法执行此操作,请稍后再试。
文章 1–20